UY29844A1 - Formulación en aerosol para la inhalación de beta-agonistas - Google Patents

Formulación en aerosol para la inhalación de beta-agonistas

Info

Publication number
UY29844A1
UY29844A1 UY29844A UY29844A UY29844A1 UY 29844 A1 UY29844 A1 UY 29844A1 UY 29844 A UY29844 A UY 29844A UY 29844 A UY29844 A UY 29844A UY 29844 A1 UY29844 A1 UY 29844A1
Authority
UY
Uruguay
Prior art keywords
inhalation
aerosol formulation
agonists
beta
radicals
Prior art date
Application number
UY29844A
Other languages
English (en)
Inventor
Kirsten Radau
Michael Nowak
Barbara Niklaus-Humke
Original Assignee
Boehringer Ingelheim Int
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=35241312&utm_source=***_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=UY29844(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Boehringer Ingelheim Int filed Critical Boehringer Ingelheim Int
Publication of UY29844A1 publication Critical patent/UY29844A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/536—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines ortho- or peri-condensed with carbocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/439—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom the ring forming part of a bridged ring system, e.g. quinuclidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/46—8-Azabicyclo [3.2.1] octane; Derivatives thereof, e.g. atropine, ***e
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/12—Aerosols; Foams
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/08—Bronchodilators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents

Abstract

La presente invención se refiere a una formulación en aerosol sin gas propelente que contiene uno o varios compuestos de la fórmula general 1, en donde los radicales R1, R2, R3 y X pueden tener los significados mencionados en las reivindicaciones y en la descripción, y otro principio, activo 2, para la inhalación.
UY29844A 2005-10-10 2006-10-06 Formulación en aerosol para la inhalación de beta-agonistas UY29844A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP05109376 2005-10-10

Publications (1)

Publication Number Publication Date
UY29844A1 true UY29844A1 (es) 2007-05-31

Family

ID=35241312

Family Applications (1)

Application Number Title Priority Date Filing Date
UY29844A UY29844A1 (es) 2005-10-10 2006-10-06 Formulación en aerosol para la inhalación de beta-agonistas

Country Status (31)

Country Link
US (3) US20070088030A1 (es)
EP (1) EP1940349B1 (es)
JP (1) JP2009511542A (es)
KR (1) KR20080059290A (es)
CN (1) CN101282712A (es)
AR (1) AR058082A1 (es)
AU (1) AU2006301330B9 (es)
BR (1) BRPI0617278A2 (es)
CA (1) CA2624786C (es)
CY (1) CY1120199T1 (es)
DK (1) DK1940349T3 (es)
EA (1) EA200800927A1 (es)
EC (1) ECSP088294A (es)
ES (1) ES2668364T3 (es)
HR (1) HRP20180713T1 (es)
HU (1) HUE039186T2 (es)
IL (1) IL190682A (es)
LT (1) LT1940349T (es)
MY (1) MY163503A (es)
NO (1) NO343363B1 (es)
NZ (1) NZ567545A (es)
PE (1) PE20070708A1 (es)
PL (1) PL1940349T3 (es)
PT (1) PT1940349T (es)
RS (1) RS57085B1 (es)
SI (1) SI1940349T1 (es)
TW (1) TWI389692B (es)
UA (1) UA99250C2 (es)
UY (1) UY29844A1 (es)
WO (1) WO2007042468A2 (es)
ZA (1) ZA200801390B (es)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7056916B2 (en) 2002-11-15 2006-06-06 Boehringer Ingelheim Pharma Gmbh & Co. Kg Medicaments for the treatment of chronic obstructive pulmonary disease
US20050272726A1 (en) * 2004-04-22 2005-12-08 Boehringer Ingelheim International Gmbh Novel medicaments for the treatment of respiratory diseases
US7220742B2 (en) * 2004-05-14 2007-05-22 Boehringer Ingelheim International Gmbh Enantiomerically pure beta agonists, process for the manufacture thereof and use thereof as medicaments
US20050255050A1 (en) * 2004-05-14 2005-11-17 Boehringer Ingelheim International Gmbh Powder formulations for inhalation, comprising enantiomerically pure beta agonists
US20050256115A1 (en) * 2004-05-14 2005-11-17 Boehringer Ingelheim International Gmbh Aerosol formulation for the inhalation of beta-agonists
JP5270343B2 (ja) * 2005-08-15 2013-08-21 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング ベータミメティックスの製造方法
WO2010057927A1 (en) * 2008-11-21 2010-05-27 Boehringer Ingelheim International Gmbh Aerosol formulation for the inhalation of beta agonists
WO2010057928A1 (en) * 2008-11-21 2010-05-27 Boehringer Ingelheim International Gmbh Aerosol formulation for the inhalation of beta agonists
GB201200525D0 (en) 2011-12-19 2012-02-29 Teva Branded Pharmaceutical Prod R & D Inc An inhalable medicament
WO2014016548A2 (en) 2012-07-27 2014-01-30 Cipla Limited Pharmaceutical composition
JP2015533131A (ja) * 2012-10-09 2015-11-19 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング 咳を治療するためのベータ２−アドレナリン受容体作動薬
US20140235627A1 (en) * 2012-12-21 2014-08-21 Boehringer Ingelheim International Gmbh ß2-ADRENOCEPTOR AGONIST FOR IMPROVEMENT OF EXERCISE TOLERANCE
US10034866B2 (en) 2014-06-19 2018-07-31 Teva Branded Pharmaceutical Products R&D, Inc. Inhalable medicament comprising tiotropium
CN107995861A (zh) * 2015-05-18 2018-05-04 格兰马克专业公司 用于雾化的泰乌托品吸入溶液
WO2018108669A1 (en) 2016-12-12 2018-06-21 Boehringer Ingelheim International Gmbh Nintedanib for use in methods for the treatment of interstitial lung diseases by coadministration with olodaterol
CN115397417A (zh) * 2020-04-16 2022-11-25 广州谷森制药有限公司 含有噻托溴铵和奥达特罗的可吸入溶液制剂
CN114259481A (zh) * 2021-11-26 2022-04-01 南京华盖制药有限公司 一种奥达特罗复方吸入溶液

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3134590A1 (de) 1981-09-01 1983-03-10 Boehringer Ingelheim KG, 6507 Ingelheim Neue benzo-heterocyclen
DE3931041C2 (de) 1989-09-16 2000-04-06 Boehringer Ingelheim Kg Ester von Thienylcarbonsäuren mit Aminoalkoholen, ihre Quaternierungsprodukte, Verfahren zu ihrer Herstellung und diese enthaltende Arzneimittel
WO1994013263A1 (en) * 1992-12-09 1994-06-23 Jager Paul D Stabilized medicinal aerosol solution formulations
BR0110331A (pt) * 2000-04-27 2003-01-07 Boehringer Ingelheim Pharma Substâncias que mimetizam beta que têm uma atividade de longa duração, processos para prepará-las e o uso das mesmas como medicamentos
DE10216036A1 (de) 2002-04-11 2003-10-23 Boehringer Ingelheim Pharma Aerosolformulierung für die Inhalation enthaltend ein Tiotropiumsalz
US7056916B2 (en) * 2002-11-15 2006-06-06 Boehringer Ingelheim Pharma Gmbh & Co. Kg Medicaments for the treatment of chronic obstructive pulmonary disease
DE10253282A1 (de) 2002-11-15 2004-05-27 Boehringer Ingelheim Pharma Gmbh & Co. Kg Neue Arzneimittel zur Behandlung von chronisch obstruktiver Lungenerkrankung
US7244728B2 (en) * 2004-03-17 2007-07-17 Boehringer Ingelheim International Gmbh Long acting betamimetics for the treatment of respiratory diseases
US20050272726A1 (en) * 2004-04-22 2005-12-08 Boehringer Ingelheim International Gmbh Novel medicaments for the treatment of respiratory diseases
US20050239778A1 (en) * 2004-04-22 2005-10-27 Boehringer Ingelheim International Gmbh Novel medicament combinations for the treatment of respiratory diseases
SG152237A1 (en) * 2004-04-22 2009-05-29 Boehringer Ingelheim Int Pharmaceutical combinations containing benzoxazine for treating respiratory diseases
US7220742B2 (en) * 2004-05-14 2007-05-22 Boehringer Ingelheim International Gmbh Enantiomerically pure beta agonists, process for the manufacture thereof and use thereof as medicaments
US20050256115A1 (en) * 2004-05-14 2005-11-17 Boehringer Ingelheim International Gmbh Aerosol formulation for the inhalation of beta-agonists
US20050255050A1 (en) * 2004-05-14 2005-11-17 Boehringer Ingelheim International Gmbh Powder formulations for inhalation, comprising enantiomerically pure beta agonists

Also Published As

Publication number Publication date
IL190682A (en) 2015-06-30
EP1940349A2 (de) 2008-07-09
PT1940349T (pt) 2018-04-30
TW200730178A (en) 2007-08-16
CA2624786A1 (en) 2007-04-19
US20100009984A1 (en) 2010-01-14
CA2624786C (en) 2015-06-16
CY1120199T1 (el) 2018-12-12
AU2006301330B9 (en) 2013-01-17
NO343363B1 (no) 2019-02-11
MY163503A (en) 2017-09-15
US20070088030A1 (en) 2007-04-19
HRP20180713T1 (hr) 2018-06-15
DK1940349T3 (en) 2018-05-28
AR058082A1 (es) 2008-01-23
KR20080059290A (ko) 2008-06-26
RS57085B1 (sr) 2018-06-29
WO2007042468A2 (de) 2007-04-19
CN101282712A (zh) 2008-10-08
ZA200801390B (en) 2009-01-28
EA200800927A1 (ru) 2008-10-30
JP2009511542A (ja) 2009-03-19
UA99250C2 (ru) 2012-08-10
TWI389692B (zh) 2013-03-21
LT1940349T (lt) 2018-05-10
US20110190284A1 (en) 2011-08-04
SI1940349T1 (en) 2018-05-31
AU2006301330A1 (en) 2007-04-19
PL1940349T3 (pl) 2018-07-31
NZ567545A (en) 2011-07-29
EP1940349B1 (de) 2018-02-14
ES2668364T3 (es) 2018-05-17
WO2007042468A3 (de) 2007-08-02
PE20070708A1 (es) 2007-08-06
BRPI0617278A2 (pt) 2011-07-19
ECSP088294A (es) 2008-04-28
HUE039186T2 (hu) 2018-12-28
NO20080801L (no) 2008-04-29
AU2006301330B2 (en) 2012-11-22
IL190682A0 (en) 2008-11-03

Similar Documents

Publication Publication Date Title
UY29844A1 (es) Formulación en aerosol para la inhalación de beta-agonistas
UY30543A1 (es) Formulacion de aerosol para la inhalacion de beta- agonistas
UY30542A1 (es) Formulacion de aerosol para la inhalacion de agonistas beta
ECSP20027480A (es) Indolil alquil amino derivados sustituidos como nuevos inhibidores de la histona desacetilasa
UY28891A1 (es) Formulacion en aerosol para la inhalacion de beta-agonistas
ECSP088246A (es) Nuevos derivados de benzotiazolona
ECSP077335A (es) Inhibidores de la interaccion entre mdm2 y p53
IL185275A0 (en) N-sulphonylpyrrole derivatives and pharmaceutical compositions containing the same
ECSP066947A (es) Combinaciones farmacológicas que contienen benzoxazina para el tratamiento de enfermedades de las vías respiratorias
ECSP088258A (es) Inhibidores de serina proteasas
AR055613A1 (es) Formas cristalinas delta y epsilon de mesilato de imatinib
ECSP099335A (es) Compuestos heterocíclicos que contienen nitrógeno y métodos de uso de los mismos
CY1109916T1 (el) Βενζιμιδαζολο-θειοφαινικες ενωσεις ως plk αναστολεις
MX2009009541A (es) Inhibidores de metaloproteasa que contienen una porcion heterociclica.
GT200600134A (es) Compuestos novedosos de derivados de aminosulfonilo
DK2134691T3 (da) Quinolinonderivativer som parp- og tank-inhibitorer
ECSP066541A (es) Nuevos derivados de piridazin-3(2h)-ona
ATE433447T1 (de) Pyrimiidinverbindungen
TW200833324A (en) Sulfonamide derivatives
UY29648A1 (es) Derivados de piridopirimidina, composiciones farmacéuticas que los contienen, procedimientos de preparación y aplicaciones
AR057148A1 (es) Combinaciones farmacologicas para el tratamiento de enfermedades de las vias respiratorias
CR7956A (es) Oxazolidinonas de indolona antibacterial intermedios para su preparacion y composiciones farmaceuticas que contienen los mismos
CR9268A (es) Nuevo derivado de diazabiciclononeno
CR9469A (es) Derivados de urea, metodos para su fabricacion y usos para los mismos
UY31349A1 (es) Inhibidores de la interaccion entre mdm2 y p53

Legal Events

Date Code Title Description
109 Application deemed to be withdrawn

Effective date: 20161007